Financing & Funds Penn cell and gene therapy spinout Interius Biotherapeutics raises another $21.5M. The 4-year-old company has now raised nearly $100 million since its inception, including the $76 million it raised last year in a Series A round co-led by Boston-based Cormorant Asset Management and

The inaugural issue of Project Evolution’s State of the U.S. AT CDMO Sector delved into the recent surge in layoffs within the Biomanufacturing CDMO markets which includes Advanced Therapies and biologic CDMOs. In that post, we discussed the factors we believe have contributed to this slowdown. Now,

CDMO Expansions: • SEQENS has entered into exclusive negotiations with Novartis for the potential acquisition of the French company Cellforcure and its cell & gene therapy development and production site. CELLforCURE’s has large-scale industrial production of cell & gene therapies. With over 10,00

CDMO Expansions: • SEQENS has entered into exclusive negotiations with Novartis for the potential acquisition of the French company Cellforcure and its cell & gene therapy development and production site. CELLforCURE’s has large-scale industrial production of cell & gene therapies. With over 10,00

Executive Movement: • Flagship Pioneering recruits former BMS, Celgene R&D chief Rupert Vessey  (PR) • Voyager Therapeutics, Inc. Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (PR) • ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Co

Facility and Expansions • MilliporeSigma Invests $25M to Expand Cell Culture Media Production in Kansas by 98,000sf. Cell culture media is an essential raw material used in the manufacture of therapies and in processes for vaccines, gene therapy, and mAb manufacturing. (genengnews) • Lonza and Ve

Private Placements • Cellares, launched as an Integrated Development and Manufacturing Organization (IDMO) dedicated to advancing clinical and industrial-scale cell therapy manufacturing, has secured $255 M in Series C funding, led by Koch Disruptive Technologies and joined by Bristol-Myers Squibb

This post marks the commencement of a series delving into the landscape of the U.S. Advanced Therapies (AT) Contract Development Manufacturing Organizations (CDMOs) sector. Before delving into the report's core content, which includes an exploration of the country's prominent biomanufacturing hubs,

Venture Capital & Private Equity Fund Updates: • Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 M. Fund III will be deployed to support and empower groundbreaking life sciences and medical technology